Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: A meta-analysis

European Journal of Clinical Pharmacology

Volumn 70, Issue 9, 2014, Pages 1041-1047

  Hou, Xiaowen ^a   Shi, Jingpu ^a   Sun, Hao ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Clopidogrel resistance; Cytochrome P450 2C19*2 (CYP2C19*2); Meta analysis; Platelet function assays; Polymorphism

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; TICLOPIDINE;

ANTIBIOTIC RESISTANCE; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; EMBASE; HUMAN; LOADING DRUG DOSE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; QUALITY CONTROL; RELIABILITY; REVIEW; SENSITIVITY ANALYSIS; THROMBOCYTE FUNCTION; THROMBOSIS; AGED; ANALOGS AND DERIVATIVES; BLOOD CLOTTING PARAMETERS; CHINA; DRUG EFFECTS; DRUG RESISTANCE; FRANCE; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; RISK; SOUTH KOREA; THROMBOCYTE AGGREGATION;

AGED; CHINA; CORONARY ARTERY DISEASE; CYTOCHROME P-450 CYP2C19; DRUG RESISTANCE; FRANCE; HUMANS; MIDDLE AGED; ODDS RATIO; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, GENETIC; REPUBLIC OF KOREA; TICLOPIDINE;

EID: 84925120149     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1714-x     Document Type: Review

References (43)

1. Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527-533 (Pubitemid 32772726)
2. Steinhubl SR, Berger PB, Mann JT 3rd et al (2002) CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411-2420 (Pubitemid 35340537)
3. Born GV (1985) Adensine diphosphate as a mediator of platelet aggregation in vivo: an editorial view. Circulation 72:741-746
4. Savi P, Pereillo JM, Uzabiaga MF et al (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891-896
5. Herbert JM, Savi P (2003) P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med 3:113-122
6. Farid NA, Kurihara A, Wrighton SA (2010) Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50:126-142
7. Lins R, Broekhuysen J, Necciari J et al (1999) Pharmacokinetic profile of 14C-labeled clopidogrel. Semin Thromb Hemost 25:29-33
8. Heestermans AA, van Werkum JW, Schömig E et al (2006) Clopidogrel resistance caused by a failure to metabolize clopidogrel into its metabolites. J Thromb Haemost 4:1143-1145
9. Wu H, Qian J, Sun A et al (2012) Association of CYP2C19 genotype with periprocedural myocardial infraction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment. Circ J 76:2773-2778
10. Park KJ, Chung HS, Kim SR et al (2011) Clinical, pharmacokinetic, and determinants of clopidogrel resistance in Korean patients with acute coronary syndrome. Korean J Lab Med 31:91-94
11. Kreutz RP, Owens J, Jin Y et al (2013) Cytochrome P450 3A4*2, PPAR-α, and ARNT polymorphisms and clopidogrel response. Clin Pharmacol 5:185-192
12. Barsky AA, Arora RR (2006) Clopidogrel resistance: myth or reality? J Cardiovasc Pharmacol Ther 11:47-53
13. Holmes MV, Perel P, Shah T et al (2011) CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306:2704-2714
14. Sofi F, Giusti B, Marcucci R et al (2011) Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 11:199-206
15. Mega JL, Simon T, Collet JP et al (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304:1821-1830
16. Mao L, Jian C, Changzhi L et al (2013) Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis 106:517-527
17. Lev EI, Patel RT, Maresh KJ et al (2006) Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resisitance. J Am Coll Cardiol 47:27-33 (Pubitemid 43005160)
18. Liu XL, Wang ZJ, Yang Q et al (2010) Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease. Chin Med J 123:3178-3183
19. Gurbel PA, Bliden KP, Zaman KA et al (2005) Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111:1153-1159 (Pubitemid 40365477)
20. Bliden KP, DiChiara J, Tantry US et al (2007) Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 49:657-66614
21. Barragan P, Bouvier JL, Roquebert PO et al (2003) Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59:295-302 (Pubitemid 36792384)
22. Bonello L, Paganelli F, Arpin-Bornet M et al (2007) Vasodilator- stimulated phosphoprotein phosphoprylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 5:1630-1636 (Pubitemid 47091403)
23. Lee JM, Park S, Shin DJ et al (2009) Relation of genetic polymorphism in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol 104:46-51
24. Tang XF, Wang J, Zhang JH et al (2013) Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol 69:1103-1112
25. Frere C, Cuisset T, Morange PE et al (2008) Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 101:1088-1093
26. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603-605
27. Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560 (Pubitemid 37088507)
28. Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455-463 (Pubitemid 30422636)
29. Hong DD (2009) Influence of cytochrome P450 enzyme (CYP2C19 and CYP3A5) polymorphism on clopidogrel responsiveness in coronary atherosclerotic heart disease patients: [D]. Fujian medical university, Fujian [Chinese]
30. Bonello-Palot N, Armero S, Paganelli F et al (2009) Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 104:1511-1515
31. Chen H, Yan W, Wu XY et al (2010) Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis. CJITWM [Chin] 30:1245-1249
32. Bonello L, Armero S, AitMokhtar Oet al (2010) Clopidogrel loading dose adjustment according to platelet reactivitymonitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol 56:1630-1636
33. Cuisset T, Quilici J, Cohen W et al (2011) Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome. Am J Cardiol 108:760-765
34. Hwang SJ, Jeong YH, Kim IS et al (2011) The cytochrome 2C19*2 and*3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Thromb Res 127:23-28
35. Zhao Q (2012) The association between CYP2C19*2 gene polymorphisms and clopidogrel resistance in the Han population of North China with coronary atherosclerotic heart disease: [D]. Hebei Medical University, Hebei [Chinese]
36. Zhang L, Chen Y, Jin Yet al (2013) Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Thromb Res 132:81-87
37. Müller I, Besta F, Schulz C et al (2003) Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89:783-787 (Pubitemid 36603418)
38. Mobley JE, Bresee SJ, Wortham DC et al (2004) Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 93:456-458 (Pubitemid 38221356)
39. Matetzky S, Shenkman B, Guetta V et al (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171-3175
40. Järemo P, Lindahl TL, Fransson SG et al (2002) Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 252:233-238
41. Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919-933
42. Qureshi Z, Hobson AR (2013) Clopidogrel "resistance": where are we now? Cardiovasc Ther 31:3-11
43. Terpening C (2010) Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol 4:117-128